Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.

The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments

Open access
Bortolato, Beatrice, F. Carvalho, Andre, K. Soczynska, Joanna, I. Perini, Giulia, S. McIntyre, Roger · 2015 · Current Neuropharmacology

Abstract

Major depressive disorder is a highly prevalent, chronic and recurring disorder, associated with substantial impairment in cognitive and interpersonal functions. Accumulating evidence suggests that inflammatory processes play an important role in the etio-pathogenesis, phenomenology, comorbidity and treatment of MDD. Suboptimal remission rates and the persistence of cognitive deficits contribute to functional impairment in MDD inviting the need for the development of mechanistically novel and domain specific treatment approaches. The MEDLINE/ Pubmed database was searched from inception to February, 9th, 2014 with combinations of the following search terms: 'TNF-alpha', 'depression', 'infliximab', 'etanercept', 'adalimumab', 'golimumab' and 'certolizumab'. Preclinical and clinical evidence linking TNF-α to MDD pathophysiology were reviewed as well as the current status of TNF-α modulators as novel agents for the treatment of MDD. Experimental models and clinical studies provide encouraging preliminary evidence for the efficacy of TNF- α antagonists in mitigating depressive symptoms and improving cognitive deficits. Further studies are warranted to confirm these data in larger randomized controlled trials in primary psychiatric populations. Translational research provides a promising perspective that may aid the development and/or repurposing of mechanism-based treatments for depressive symptoms and cognitive impairment in MDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x13666150630171433

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) Schematic representation of inflammatory pathways involved in neuroprogression. Peripheral pro-inflammatory stimuli activate microglial cells, which initiate an inflammatory cascade within the brain secreting cytokines, chemokines, adhesion molecules and reactive nitrogen and oxygen species (RNS and ROS). Astrocytes further amplify the immune response and are responsible of impaired neurovascular coupling and reduced trophic support to neurons and other glial cells. Immunoexcitotoxicity is mediated by the production of the NMDA agonist QUIN, increased TNF-mediated density and activity of AMPA and NMDA receptors and decreased Glu reuptake. The combined effect of immune mediators, nitrosative and oxidative burden and reduced production of growth factors leads foster mitochondrial dysfunction and consequent apoptotic death and impaired neuroplasticity. GLU, glutamate; IDO, indolamine 2,3 dioxygenase; 5HT, serotonin; IFN, interferon; IL, interleukin; NGF, nerve growth factor; BDNF, brain derived neurotrophic factor; NMDA, N-methyl-Daspartate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic calcium-permeable receptors; QUIN, quinolinic acid; RNS, reactive nitrogen species; ROS, reactive oxygen species; Th1, T Helper 1; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; CCL, C-C chemokine ligands; CXCL (C–X–C motif) ligand chemokine; MCP, monocyte chemotactic protein.
Fig. (1) Schematic representation of inflammatory pathways involved in neuroprogression. Peripheral pro-inflammatory stimuli activate microglial cells, which initiate an inflammatory cascade within the brain secreting cytokines, chemokines, adhesion molecules and reactive nitrogen and oxygen species (RNS and ROS). Astrocytes further amplify the immune response and are responsible of impaired neurovascular coupling and reduced trophic support to neurons and other glial cells. Immunoexcitotoxicity is mediated by the production of the NMDA agonist QUIN, increased TNF-mediated density and activity of AMPA and NMDA receptors and decreased Glu reuptake. The combined effect of immune mediators, nitrosative and oxidative burden and reduced production of growth factors leads foster mitochondrial dysfunction and consequent apoptotic death and impaired neuroplasticity. GLU, glutamate; IDO, indolamine 2,3 dioxygenase; 5HT, serotonin; IFN, interferon; IL, interleukin; NGF, nerve growth factor; BDNF, brain derived neurotrophic factor; NMDA, N-methyl-Daspartate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic calcium-permeable receptors; QUIN, quinolinic acid; RNS, reactive nitrogen species; ROS, reactive oxygen species; Th1, T Helper 1; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; CCL, C-C chemokine ligands; CXCL (C–X–C motif) ligand chemokine; MCP, monocyte chemotactic protein.CC BY-NC · PubMed Central
Fig. (2) TNF-α enhances excitotoxicity via upregulation of glutaminase, suppression of glutamine synthetase, impaired glutamate reuptake and increased trafficking of AMPA calcium‐ permeable receptors to the synaptic membrane and endocytosis of GABA-A receptors. These mechanisms, in association with alterations in 5-HT, DA, NA mediated neurotransmission, promote glial dysfunction and neuronal degeneration.
Fig. (2) TNF-α enhances excitotoxicity via upregulation of glutaminase, suppression of glutamine synthetase, impaired glutamate reuptake and increased trafficking of AMPA calcium‐ permeable receptors to the synaptic membrane and endocytosis of GABA-A receptors. These mechanisms, in association with alterations in 5-HT, DA, NA mediated neurotransmission, promote glial dysfunction and neuronal degeneration.CC BY-NC · PubMed Central
Fig. (3) Simplified diagrams of the structures of 5 TNF antagonists. Infliximab is a mouse/human chimeric monoclonal antibody of IgG1 isotype. Adalimumab and golimumab are fully human monoclonal antibodies. Certolizumab is a PEGylated Fab' fragment of a humanized IgG1 monoclonal antibody. Etanercept is a fusion protein of TNFR2 (p75) and the Fc region of human IgG1.
Fig. (3) Simplified diagrams of the structures of 5 TNF antagonists. Infliximab is a mouse/human chimeric monoclonal antibody of IgG1 isotype. Adalimumab and golimumab are fully human monoclonal antibodies. Certolizumab is a PEGylated Fab' fragment of a humanized IgG1 monoclonal antibody. Etanercept is a fusion protein of TNFR2 (p75) and the Fc region of human IgG1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 156 references

Cited by

See all 162

Metadata

Authors
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R.
Affiliations
University of Padua (IT)
Venue
Current Neuropharmacology
Published
2015-10-13
Volume
13
Issue
5
Pages
558-576
ISSN
1570-159X (ISSN-L)
OpenAlex
W2275844848
Cited by
142
References
156
Citations by year
2026: 10 · 2025: 13 · 2024: 9 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 14 · 2019: 11 · 2018: 14 · 2017: 15 · 2016: 3
FWCI
0.60
Type
journal article
Language
en
Open access
Locations
  • Current Neuropharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
major depressive disorder, TNF-α, cognitive impairment, neuroinflammation, TNF-alpha inhibitors, infliximab, etanercept, adalimumab, golimumab, certolizumab, translational research, drug repurposing
MeSH terms
Animals, Cognition Disorders, Major Depressive Disorder, Humans, Tumor Necrosis Factor-alpha, MEDLINE

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. https://app.cochat.ai/papers/10.2174/1570159x13666150630171433
The paper
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015). The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Current Neuropharmacology. https://doi.org/10.2174/1570159x13666150630171433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.